Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Health Catalyst ( (HCAT) ) has issued an announcement.
On January 20, 2026, Health Catalyst, Inc. announced that its Board of Directors had decided Chief Commercial Officer Kevin Freeman would leave that role effective February 1, 2026. To support continuity in commercial operations, the company and Freeman plan for him to receive separation benefits under the company’s Executive Severance Plan in exchange for a general release of claims and then transition into a senior advisor position under an anticipated independent contractor agreement starting February 2, 2026, signaling an effort to manage leadership change while preserving access to his expertise.
The most recent analyst rating on (HCAT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Health Catalyst stock, see the HCAT Stock Forecast page.
Spark’s Take on HCAT Stock
According to Spark, TipRanks’ AI Analyst, HCAT is a Neutral.
Health Catalyst’s overall stock score is primarily impacted by its financial performance challenges, including consistent losses and negative profitability metrics. While the earnings call provided some positive insights, such as exceeding financial guidance and strategic operational successes, the technical analysis and valuation remain weak. The recent corporate event of appointing a new President is a positive strategic move, but it does not outweigh the significant financial and valuation concerns.
To see Spark’s full report on HCAT stock, click here.
More about Health Catalyst
Average Trading Volume: 679,524
Technical Sentiment Signal: Sell
Current Market Cap: $156.3M
Find detailed analytics on HCAT stock on TipRanks’ Stock Analysis page.